The primary culture cells and/or conditioned medium retained in the primary culture container are periodically used to supplement the bulk culture.
The media are particularly suitable for the primary culture and long-term culture of human fetal cells.
The method of the invention involves biopsy of an appropriate tissue, primary culture in a certain medium, proliferative culture in a second medium, and differentiative culture in a third medium.
The method comprises inserting autologous growth factors into a serum-free stem cell culture medium to perform the primary culture and subculture of human adult stem cells.
If no CPE has developed after the primary incubation for 7 to 10 days, subcultivation shall be performed to fresh cell cultures utilising a cell area similar to that of the primary culture.
The invention also concerns the primary-culture tumour cells that can be obtained by this method from the tumour tissue, in particular primary-culture tumour cells from breast carcinoma.
Furthermore, this composition of culture media can be widely applied for all kinds of primarily-cultured cells, because it is optimized for both stem cells and primarily-cultured fibroblasts.
The medium is particularly adapted for the primary or secondary culture of epithelial cells.
The present invention relates to methods for obtaining primary-culture tumour cells from tumour tissue.
Primarily cultured adipocytes for gene therapy which stably sustain a foreign gene encoding a protein secreted extracellularly.
Thus, a method of transferring a foreign gene into primarily cultured adipocytes appropriate for ex vivo gene therapy, which can be easily collected and transplanted and can be eliminated after the transplantation, is established.
In particular, primarily cultured adipocytes appropriate for ex vivo gene therapy which stably sustain a foreign gene encoding a protein secreted extracellularly are established.
Finally, the invention relates to the use of these primary-culture tumour cells for, among other things, determining an individual course of tumour treatment, or for testing and screening of new therapeutic agents against tumours.